Aspirin: An alternative for pulmonary embolism prophylaxis after arthroplasty?

Clinical Orthopaedics and Related Research

Volumn 472, Issue 2, 2014, Pages 482-488

  Raphael, Ibrahim J ^a   Tischler, Eric H ^a   Huang, Ronald ^a   Rothman, Richard H ^a   Hozack, William J ^a   Parvizi, Javad ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; ARTHROPLASTY; CONFERENCE PAPER; DATA BASE; DEEP VEIN THROMBOSIS; FEAR; FEMALE; HEMATOMA; HOSPITALIZATION; HUMAN; LAW SUIT; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; ORTHOPEDIC SURGEON; PRIORITY JOURNAL; PROPENSITY SCORE; WOUND COMPLICATION; WOUND INFECTION;

ADULT; AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHILADELPHIA; PROPENSITY SCORE; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN; WOUND HEALING;

EID: 84893694968     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-013-3135-z     Document Type: Conference Paper

References (42)

1. Anon. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355:1295-1302.
2. Berend KR, Lombardi AV Jr. Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin. Am J Orthop. 2006;35:24-29.
3. Bjørnarå BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006;88:386-391.
4. Boyd HS. VTE prevention in major orthopedic surgery. Cleve Clin J Med. 2008;75:471-472; author reply 472-473.
5. Bozic KJ, Vail TP, Pekow PS, Maselli JH, Lindenauer PK, Auerbach AD. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25:1053-1060.
6. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001;16:293-300.
7. Callaghan JJ, Warth LC, Hoballah JJ, Liu SS, Wells CW. Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. J Arthroplasty. 2008;23(6 suppl 1):20-24.
8. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, Fitzgerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
9. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
11. Cusick LA, Beverland DE. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients. J Bone Joint Surg Br. 2009;91:645-648.
12. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
13. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr; American College of Chest Physicians. Prevention of VTE in Orthopedic Surgery Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e278S-e325S.
14. Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement: results from a regional hip register. J Bone Joint Surg Br. 1997;79:896-899.
15. Fitzgerald RH Jr, Spiro TE, Trowbridge AA, Gardiner GA Jr, Whitsett TL, O'Connell MB, Ohar JA, Young TR; Enoxaparin Clinical Trial Group. Prevention of venous thromboembolic disease during primary total knee arthroplasty. J Bone Joint Surg Am. 2001;83:900-906.
16. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Ginsberg JS, Lieberman JR, Webster AK, Whittle JP, Peters GR, Colwell CW Jr. Ximelagatran versus warfarin for the prevention of thromboembolism after total knee arthroplasty: a randomized double blind trial. Ann Intern Med. 2002;137:648-655.
17. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Kessler C, Rosenberg A, Johanson NA. Prevention of deep vein thrombosis after total hip arthroplasty: a comparison of warfarin and dalteparin. J Bone Joint Surg Am. 1997;79:1365-1372.
18. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
19. Hamilton SC, Whang WW, Anderson BJ, Bradbury TL, Erens GA, Roberson JR. Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. J Arthroplasty. 2012;27:1594-1598.
20. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost. 1997;77:32-38.
21. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
22. Hull RD, Raskob GE. Prophylaxis of venous thromboembolic disease following hip and knee surgery. J Bone Joint Surg Am. 1986;68:146-150.
23. Johanson NA, Lachiewicz PF, Lieberman JR, Lotke PA, Parvizi J, Pellegrini V, Stringer TA, Tornetta P 3rd, Haralson RH 3rd, Watters WC 3rd. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009;91:1756-1757.
24. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty: a randomized, double blind trial, comparing enoxaparin with warfarin. Ann Intern Med. 1996;124:619-626.
25. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Canadian Collaborative Group. Chest. 1998;114(2 suppl evidence):115S-118S.
26. Lieberman JR, Wollaeger J, Dorey F, Thomas BJ, Kilgus DJ, Grecula MJ, Finerman GA, Amstutz HC. The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty. J Bone Joint Surg Am. 1997;79:319-325.
27. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res. 2006;452:175-180.
28. Lotke PA, Palevsky H, Keenan AM, Meranze S, Steinberg ME, Ecker ML, Kelley MA. Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996;324:251-258.
29. Paiement G, Wessinger SJ, Waltman AC, Harris WH. Low-dose warfarin versus external pneumatic compression for prophylaxis against venous thromboembolism following total hip replacement. J Arthroplasty. 1987;2:23-26.
30. Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does "excessive" anticoagulation predispose to periprosthetic infection? J Arthroplasty. 2007;22(6 suppl 2):24-28.
31. Parvizi J, Kahl LK, Dalsey C. Aggressive anticoagulation after TJA: an evaluation of the ACCP guidelines for thromboprophylaxis. J Long Term Eff Med Implants. 2007;17:359-365.
32. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):234S-264S.
33. Pellegrini VD Jr, Sharrock NE, Paiement GD, Morris R, Warwick DJ. Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment. Instr Course Lect. 2008;57:637-661.
34. Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG, Ma Y, Roberts T, Sharrock N, Salvati E. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br. 2012;94:113-121.
35. Pulido L, Parvizi J, Macgibeny M, Sharkey PF, Purtill JJ, Rothman RH, Hozack WJ. In hospital complications after total joint arthroplasty. J Arthroplasty. 2008;23(6 suppl 1):139-145.
36. Reitman RD, Emerson RH, Higgins LL, Tarbox TR. A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. J Arthroplasty. 2003;18:161-168.
37. Sachs RA, Smith JH, Kuney M, Paxton L. Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty. J Arthroplasty. 2003;18:389-395.
38. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop Relat Res. 2008;466:714-721.
39. Vresilovic EJ, Hozack WJ, Booth RE Jr, Rothman RH. Comparative risk of early postoperative pulmonary embolism after cemented total knee versus total hip arthroplasty with low-dose warfarin prophylaxis. Am J Knee Surg. 1996;9:2-6.
40. Vulcano E, Gesell M, Esposito A, Ma Y, Memtsoudis SG, Gonzalez Della Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012;36:1995-2002.
41. White RH, Meehan JP, Romano PS. Re: Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25:667; author reply 667-668.
42. Winters BS, Solarz M, Jacovides CL, Purtill JJ, Rothman RH, Parvizi J. Overdiagnosis of pulmonary embolism: evaluation of a hypoxia algorithm designed to avoid this catastrophic problem. Clin Orthop Relat Res. 2012;470:497-502.